| Literature DB >> 32292884 |
Abstract
Elderly patients are having high mortality rates from COVID-19/SARS-CoV-2 infection compared to younger patients. The SARS-CoV-2 virus uses the ACE2 receptor as the entry point to the host cells. ARBs/ACEIs which are widely used in elderly patients, have been found to be associated with overexpression of ACE2.To decrease the severity of COVID-19 infection, ARB/ACEI should be switched to another class drug not known to cause a rise in ACE2 until the COVID-19 infection subsides. Specific human immunoglobulin can be tried for COVID-19 patients with critical conditions under supervision. © Springer Nature Switzerland AG 2020.Entities:
Keywords: ACE2; ACEI; ARB; COVID-19; SARS-CoV-2
Year: 2020 PMID: 32292884 PMCID: PMC7140724 DOI: 10.1007/s42399-020-00271-7
Source DB: PubMed Journal: SN Compr Clin Med ISSN: 2523-8973